An update on clinicopathological, immunohistochemical, and molecular profiles of XXXX of the lung.

@entity1 @entity6628 @entity7041 @entity3079 @entity10922 @entity5 @entity984 @entity470 @entity2225 @entity420 @entity5822 @entity2220
UNASSIGNED: @entity3079 is a rare @entity2220 characterized by abundant pools of extracellular mucin and scant malignant epithelium. Because of the rarity of these @entity5 , many of the reported clinicopathological and immunohistochemical characteristics are contradictory. Moreover, the molecular alterations that underlie these @entity5 are unknown. We present the clinicopathological, immunohistochemical, and molecular features of 13 cases of @entity3079 of the lung. The @entity1 were 9 @entity1 and 4 @entity1 between the ages of 48 and 86 years. Surgical resection and staging were performed in all @entity1 . Seven @entity1 were in stage T1N0M0, 3 in T2N0M0, 2 in T2N1M0, and 1 in T2N0M1. The @entity5 was 100% mucinous in 9 @entity1 , whereas in 4 cases, the lesions consisted of 50% to 90% mucin pools with the remainder being a noncolloid @entity420 component ranging in morphology from bronchioalveolar to acinar, papillary, solid, or mixed patterns. Follow-up ranged from 35 to 128 months. Three @entity1 died, 1 of disease and 2 of unrelated causes. The remaining 10 @entity1 are alive at the time of reporting, 3 with recurrent disease. Immunohistochemical studies showed @entity5822 , @entity2225 , and @entity6628 expression in all @entity5 , whereas @entity10922 , surfactant A, and napsin A were not present or were only focally positive in most cases. Analysis showed @entity984 mutations in 2 cases. All @entity5 were negative for @entity7041 gene rearrangement and @entity470 mutation. Our study highlights the clinicopathological, immunohistochemical, and molecular features of @entity2220 and attempts to clarify some misconceptions regarding this rare @entity5 .
